Holen Sie sich die Stockscreener-App
71.19
1.59%
-1.15
Handel nachbörslich:
71.19
Schlusskurs vom Vortag:
$72.34
Offen:
$73.21
24-Stunden-Volumen:
1.97M
Relative Volume:
0.91
Marktkapitalisierung:
$11.76B
Einnahmen:
$943.38M
Nettoeinkommen (Verlust:
$-380.99M
KGV:
-28.86
EPS:
-2.4667
Netto-Cashflow:
$-325.67M
1W Leistung:
-3.85%
1M Leistung:
-11.67%
6M Leistung:
+12.71%
1J Leistung:
+116.38%
1-Tages-Spanne:
$70.42
$74.16
1-Wochen-Bereich:
$70.42
$77.03
52-Wochen-Spanne:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
71.19 | 11.95B | 943.38M | -380.99M | -325.67M | -2.4667 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
IONS SEC FilingsIonis Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Connor Clark & Lunn Investment Management Ltd. Raises Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Atika Capital Management LLC Invests $1.41 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Sell: Brett Monia Sells 160,773 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $9,525,584.00 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 34,103 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $2,827,460.45 in Stock - MarketBeat
Ionis Pharmaceuticals Presents at Barclays Healthcare Conference - National Today
Ionis (NASDAQ: IONS) EVP sells 37,277 shares under 10b5-1 plan - Stock Titan
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Capital World Investors Has $832.32 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharma director Diaz sells $4.35m in IONS stock By Investing.com - Investing.com Nigeria
Ionis pharma director Loscalzo sells $82k in shares - Investing.com Nigeria
Ionis pharma director Klein sells $1.7 million in IONS stock - Investing.com Nigeria
Ionis Pharmaceuticals at Leerink Global Healthcare: Strategic Moves in 2026 By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Announces Board Changes: Parshall and Wender to Retire, Reikes Rejoins in 2026 - Minichart
Ionis announces changes to Board of Directors - pharmiweb.com
Ionis Pharmaceuticals Announces Board Retirements and New Appointment - TipRanks
Ionis Pharmaceuticals (NASDAQ: IONS) plans board refresh as Parshall, Wender retire and Reikes returns - Stock Titan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Position Raised by Rhenman & Partners Asset Management AB - MarketBeat
GW&K Investment Management LLC Sells 184,823 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
DCF Advisers LLC Has $7.09 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
August 21st Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis pharma director Loscalzo sells $82k in shares By Investing.com - Investing.com UK
Insider Sell: Joseph Loscalzo Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 20,106 Shares of Stock - MarketBeat
C Frank Bennett Sells 85,089 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Allene Diaz Sells 54,878 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharma director Diaz sells $4.35m in IONS stock - Investing.com South Africa
Ionis Pharma EVP Devers sells $1.59 million in IONS stock By Investing.com - Investing.com Canada
Ionis pharma director Klein sells $1.7 million in IONS stock By Investing.com - Investing.com Australia
ARK Investment Management LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Legato Capital Management LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
HC Wainwright Analysts Raise Earnings Estimates for IONS - MarketBeat
American Century Companies Inc. Grows Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals (IONS) Receives Price Target Raise to $104 by Leerink Partners | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $104.00 at Leerink Partners - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Powerhouse with 15.60% Upside Potential - DirectorsTalk Interviews
Rafferty Asset Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
FDA Priority Review And 2026 Outlook Might Change The Case For Investing In Ionis (IONS) - Sahm
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story - Yahoo Finance
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story - simplywall.st
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance - Yahoo Finance
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) - Yahoo Finance
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by Wall Street Zen to Sell - MarketBeat
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):